Sionna Therapeutics, Inc.

NASDAQ:SION

Biotechnology

Healthcare
$2.97 +1.85%

+$0.68 today

Market cap
$134.35M
Beta
1.29
P/E (TTM)
-19.7
EPS (TTM)
-$1.90
52W Low $13.81High $48.45

Volume 0.52M

Average 0.39M

SION Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Sionna Therapeutics, Inc.NASDAQ: SION

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables outflow grows to $0

Q1 FY2026 accounts receivables was $0, compared with $0 a year earlier. Trailing-twelve-month accounts receivables was $0.

Context

  • Accounts receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Accounts Receivables vs competitors

How SION compares with its peers on the latest reported figures

  • SION's LTM Mar 2026 accounts receivables of $0 is the 8th largest of the 11 companies compared; the peer median is $14.98M.
SION Competitors Peer median
Accounts Receivables for SION and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZYMEZymeworks Inc.LTM Sep 2026$267.78M +5106.7%—100.7%
ABCLAbCellera Biologics Inc.LTM Sep 2026$43.84M +19.1%+34.8%64.6%
ARDXArdelyx, Inc.LTM Mar 2026$36.37M +98.7%+25.1%8.5%
JANXJanux Therapeutics, Inc.LTM Mar 2026$35M +401.4%—161.9%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$20M ——100.0%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$9.97M +11.8%-7.4%3.2%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$265K -134.8%+95.9%236.6%
SIONSionna Therapeutics, Inc.LTM Mar 2026$0 ———
IMNMImmunome, Inc.LTM Sep 2026$0 ———
BHVNBiohaven Ltd.LTM Jun 2026$0 ———
VERAVera Therapeutics, Inc.LTM Jun 2026$0 ———
Peer median (excluding SION) $14.98M+58.9%+29.9%100.0%

Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(40.24M)(47.26M)(61.69M)(75.27M)
Depreciation & Amortization122K583K668K(3.05M)
Deferred Income Tax0000
Stock-Based Compensation1.69M2.26M3.71M12.07M
Change in Working Capital2.76M(783K)(3.08M)(2.65M)
Accounts Receivables0000
Inventory0000
Accounts Payables(1.51M)162K467K(417K)
Other Working Capital4.28M(945K)(3.54M)(2.24M)
Other Non-Cash Items(400K)1.51M7.6M2.61M
Operating Cash Flow(36.07M)(43.7M)(52.79M)(66.3M)
Capital Expenditures(1.87M)(1.12M)(27K)(377K)
Acquisitions (Net)0000
Purchases of Investments(40.39M)(23.53M)(182.84M)(325.03M)
Sales of Investments13M52M55.96M206.65M
Other Investing Activities0000
Investing Cash Flow(29.26M)27.35M(126.91M)(118.75M)
Debt Repayment0000
Common Stock Issued00178.97M205.71M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities64K31K00
Financing Cash Flow110.86M31K178.97M205.71M
Effect of Forex Changes0000
Net Change in Cash45.52M(16.32M)(733K)20.66M
Free Cash Flow(37.94M)(44.82M)(52.81M)(66.67M)

Sionna Therapeutics, Inc.

NASDAQ:SION

Intrinsic Alpha fair value

Locked

Current Price

$2.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.